Signal Transduction of a Novel WBP2 Oncogene

Abstract

WW-domain binding protein 2 (WBP2) was first discovered as a ligand of the WW-domain of Yes-associated Protein (YAP). A decade after its discovery, our laboratory implicated WBP2 in breast cancer development. Since then, WBP2 had also been shown to be involved in other types of cancer, such as glioma, liver and skin cancer. The oncogenic properties of WBP2 are mediated by several oncogenic signalling pathways, including EGFR, PI3K/Akt, ER, Wnt, and Hippo signalling pathways. Recently, WBP2 was demonstrated to play roles in diseases other than cancer, such as infertility and deafness. In the near future, we envisage a growing body of literature surrounding the role of WBP2 in more cancer types and signalling pathways.